XML 16 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Operating expenses:        
Research and development $ 3,110,752 $ 3,260,938 $ 9,005,811 $ 28,196,970
General and administrative 2,618,679 2,824,589 12,524,503 16,004,308
Total operating expenses 5,729,431 6,085,527 21,530,314 44,201,278
Loss from operations (5,729,431) (6,085,527) (21,530,314) (44,201,278)
Interest expense, net (62,340) (12,459) (124,944) (168,239)
Merger transaction costs (7,499,353)
Change in fair value of warrants 64,959 7,613 57,406 14,428
Change in fair value of convertible promissory notes 48,468,678
Change in fair value of written call option derivative liabilities 206,150 (7,064)
Loss on issuance of commitment shares (890,000)
Net loss (5,726,812) (5,884,223) (21,597,852) (4,282,828)
Net loss attributable to common stockholders, basic and diluted $ (5,862,428) $ (5,909,428) $ (22,007,715) $ (864,521)
Net loss attributable to common stockholders, basic $ (0.03) $ (0.03) $ (0.12) $ (0.01)
Net loss attributable to common stockholders, diluted $ (0.03) $ (0.03) $ (0.12) $ (0.01)
Weighted-average common stock outstanding, basic 196,028,784 170,174,533 187,086,621 160,000,569
Weighted-average common stock outstanding, diluted 196,028,784 170,174,533 187,086,621 160,000,569